More than 70% of clinical study data now arrives from external vendors, each delivering files in its own format on its own schedule. That single operational fact is what makes late-stage data remediation so expensive: by the time a standards problem surfaces at submission, fixing it means renegotiating with vendors, reprocessing datasets, and burning reviewer time that no team has to spare.
Certara’s External Data Accelerator addresses this upstream. The offering pairs senior external data specialists with Pinnacle 21 Data Exchange, the validation engine the FDA has used for over a decade to assess submission quality, so incoming vendor data is mapped and checked against CDISC standards before it enters the study database rather than after. The practical shift is when the problem gets caught: a vendor file that fails a conformance rule on arrival can be corrected in days; the same failure discovered during submission review can take months.
Timing matters because three CDISC standards are converging in 2026, including a public review period running through November for SENDIG v4.0 with Rules and SDTM v3.0. Sponsors managing multiple external data streams through that transition face a version-control problem on top of an already fragmented vendor landscape. The average clinical study draws data from four or more distinct sources, according to Certara’s own analysis of non-CRF data in clinical trials, covering biomarkers, labs, imaging, ePRO platforms, and wearables. Each source is a potential mismatch point when standards change mid-study.
The External Data Accelerator positions standards conformance as a design decision made at study setup, not a cleanup task assigned to a data manager six weeks before a filing deadline. Whether that framing holds operationally depends on how tightly the specialist team can enforce vendor data agreements early enough to influence what the vendor actually delivers. The real test will be whether submission packages built through this model clear FDA technical rejection rates faster than industry baselines.
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
